PETX stock forecast
Our latest prediction for Aratana Therapeutics, Inc.'s stock price was made on the Dec. 17, 2018 when the stock price was at 5.97$.
In the short term (2weeks), PETX's stock price should underperform the market by 0.00%. During that period the price should oscillate between -7.05% and +8.58%.
In the medium term (3months), PETX's stock price should outperform the market by 0.77%. During that period the price should oscillate between -16.47% and +26.02%.Get email alerts
Create a solid portfolio with PETX
About Aratana Therapeutics, Inc.
Aratana Therapeutics, Inc. engages in the development and commercialization of pet therapeutics. Its portfolio includes NOCITA, ENTYCE, and GALLIPRANT. NOCITA (bupivacaine liposome injectable suspension) acts as a local post-operative analgesia for cranial cruciate ligament surgery in dogs, and as a peripheral nerve block to provide regional post-operative analgesia following onychectomy in cats. ENTYCE(capromorelin oral solution) is intended for appetite stimulation in dogs. GALLIPRANT (grapiprant tablets) is for the control of pain and inflammation associated with osteoarthritis in dogs. The company was founded by Linda Rhodes and Steven St. Peter on December 1, 2010 and is headquartered in Leawood, KS.
At the moment the company generates 41M USD in revenues.
On its last earning announcement, the company reported a loss of -0.50$ per share.
The book value per share is 1.96$
Three months stock forecastDec. 17, 2018
|Revenue USD||Gross Margin||Operating Income||Operating Margin||Net Income||Earnings Per Share||Dividends||Payout Ratio||Shares||Book Value Per Share||Operating Cash Flow||Cap Spending||Free Cash Flow|